Cargando…

HLA-haploidentical hematopoietic stem cell transplantation with low-dose thymoglobulin GVHD prophylaxis for an adult T cell leukemia/lymphoma patient treated with pretransplant mogamulizumab

Detalles Bibliográficos
Autores principales:	Hirosawa, Makoto, Higashi, Takehiro, Iwashige, Atsushi, Yamaguchi, Takahiro, Tsukada, Junichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226989/ https://www.ncbi.nlm.nih.gov/pubmed/27766392 http://dx.doi.org/10.1007/s00277-016-2856-y

Ejemplares similares

Reduced-intensity haploidentical peripheral blood stem cell transplantation using low-dose thymoglobulin for aggressive adult T cell leukemia/lymphoma patients in non-complete remission
por: Hirosawa, Makoto, et al.
Publicado: (2020)

Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study
por: Hirosawa, Makoto, et al.
Publicado: (2022)

Hairy cell leukemia presenting with progressive pericarditis and pleuritis
por: Iwashige, Atsushi, et al.
Publicado: (2018)

Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysis
por: Gao, Wen-hui, et al.
Publicado: (2023)

Editorial: The Immunobiology of HLA-Haploidentical Hematopoietic Cell Transplantation
por: Mancusi, Antonella, et al.
Publicado: (2020)

Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation
por: Hashimoto, Daigo, et al.
Publicado: (2011)

Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT
por: Toor, A, et al.
Publicado: (2008)

Allodepleted T‐cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft‐versus‐host disease (GVHD) in the absence of GVHD prophylaxis
por: Roy, Denis Claude, et al.
Publicado: (2019)

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
por: Lorentino, Francesca, et al.
Publicado: (2022)

Tregs combined with mature donor T cells hasten immune reconstitution without triggering GvHD in HLA haploidentical transplantation
por: Di Ianni, Mauro, et al.
Publicado: (2011)

PB2439: EARLIER ENGRAFTMENT WITHOUT INCREASE OF GVHD IN HIGHER DOSE OF CD34+ CELLS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Tan, Tran-Der, et al.
Publicado: (2023)

Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure
por: Stenger, Elizabeth O., et al.
Publicado: (2023)

CD4(+)FOXP3(+) Regulatory T Cell Therapies in HLA Haploidentical Hematopoietic Transplantation
por: Mancusi, Antonella, et al.
Publicado: (2019)

Transmission of Human T-Lymphotropic Virus Type I to Donor-Origin T Cells During Allogeneic Hematopoietic Stem Cell Transplantation
por: Hirosawa, Makoto, et al.
Publicado: (2022)

GVHD Prophylaxis 2020
por: Gooptu, Mahasweta, et al.
Publicado: (2021)

Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia
por: Huang, Zhenli, et al.
Publicado: (2022)

αβT- and B-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation in children with myelodysplastic syndromes
por: Merli, Pietro, et al.
Publicado: (2022)

Review of Haploidentical Hematopoietic Cell Transplantation
por: Khan, Mehreen A., et al.
Publicado: (2018)

An avoidable cause of thymoglobulin anaphylaxis
por: Brabant, S., et al.
Publicado: (2017)

Removal of CD276(+) cells from haploidentical memory T-cell grafts significantly lowers the risk of GVHD
por: Hashimoto, Hisayoshi, et al.
Publicado: (2021)

Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation
por: Ueda Oshima, Masumi, et al.
Publicado: (2023)

Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience
por: Zhou, Ling, et al.
Publicado: (2020)

Strategies for Potentiating NK-Mediated Neuroblastoma Surveillance in Autologous or HLA-Haploidentical Hematopoietic Stem Cell Transplants
por: Bottino, Cristina, et al.
Publicado: (2022)

Haploidentical Hematopoietic Stem-Cell Transplantation in Adults
por: Alshemmari, Salem, et al.
Publicado: (2011)

Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide
por: Mariotti, Jacopo, et al.
Publicado: (2019)

Evaluation of Cyclosporine Pharmacokinetic, Monitoring, and Dosing Parameters for GVHD Prophylaxis in Hematopoietic Stem Cell Transplant (HSCT) Recipients
por: Tafazoli, Ali, et al.
Publicado: (2019)

Thymoglobulin – new approaches to optimal outcomes
por: Delia Moiceanu, Andreea, et al.
Publicado: (2009)

Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
por: van der Velden, Walter J. F. M., et al.
Publicado: (2021)

PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
por: Al-Homsi, A. Samer, et al.
Publicado: (2023)

The Addition of Sirolimus to GVHD Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis of Efficacy and Safety
por: Chen, Xiaoli, et al.
Publicado: (2021)

Higher graft cell dose does not influence development of acute or chronic GVHD in haploidentical transplantation using PTCy
por: Nawas, Mariam T., et al.
Publicado: (2023)

Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation
por: Baumeister, Susanne H. C., et al.
Publicado: (2020)

Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders
por: Albert, Michael H., et al.
Publicado: (2021)

T-cell depleted haploidentical hematopoietic cell transplantation for pediatric malignancy
por: Takahashi, Takuto, et al.
Publicado: (2022)

P1396: EFFICACY AND SAFETY COMPARISON OF CALCINEURIN INHIBITORS USED FOR GVHD PROPHYLAXIS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMIA
por: Zhumatayev, S., et al.
Publicado: (2022)

Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide
por: Maeda, Yoshinobu
Publicado: (2021)

Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy
por: Fujimura, Taku, et al.
Publicado: (2018)

Loss of Mismatched HLA Detected in the Peripheral Blood of an AML Patient who Relapsed After Haploidentical Hematopoietic Stem Cell Transplantation
por: Park, Borae G., et al.
Publicado: (2015)

Comparison of porcine ALG and rabbit ATG on outcomes of HLA-haploidentical hematopoietic stem cell transplantation for patients with acquired aplastic anemia
por: Chen, Juan, et al.
Publicado: (2022)

Delayed kidney transplantation after HLA-haploidentical hematopoietic cell transplantation in a young woman with myelodysplastic syndrome with renal failure
por: Miller, Kevin C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m896o4q3essvhatp75ttspkq5v